阿帕替尼单药治疗早期非小细胞肺癌：一例病例报告。

Xu Jiafang, Hu Qingjie, Yin Siqi, He Huifang, Li Hai, Yang Ruiqi, Song Meizi, Wang Chaoqun, Liu Yu

Reproductive Medicine Center, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.

Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.

J Cardiothorac Surg. 2024 Oct 1;19(1):557. doi: 10.1186/s13019-024-03088-w.

Stage I non-small cell lung cancer (NSCLC) accounts for about 15% of incident cancer cases. Prognosis is poor, with a metastasis and recurrence rate of 38% within 2 years of surgery and an overall 5-year survival rate of 54-60%. Here, we report successful apatinib monotherapy of early NSCLC in a patient who had declined surgery, radiofrequency ablation, and immunotherapy. The patient received apatinib for 64 months without clinical, laboratory, or radiographic evidence of disease progression. The curative effect was judged to be stable and safe.The role of apatinib as monotherapy for patients with early stage NSCLC who are not candidates for surgery or radiotherapy, or as an adjunct to standard therapy, deserves further study.

I期非小细胞肺癌（NSCLC）约占新发癌症病例的15%。其预后较差，术后2年内转移和复发率为38%，总体5年生存率为54% - 60%。在此，我们报告了1例拒绝手术、射频消融和免疫治疗的早期NSCLC患者接受阿帕替尼单药治疗取得成功的病例。该患者接受阿帕替尼治疗64个月，无疾病进展的临床、实验室或影像学证据。疗效判定为稳定且安全。阿帕替尼作为无法进行手术或放疗的早期NSCLC患者的单药治疗，或作为标准治疗的辅助治疗，其作用值得进一步研究。